From Utrecht U-The Netherlands: Should non-inferiority drug trials be banned altogether?

http://www.ncbi.nlm.nih.gov/pubmed/23328201

Drug Discov Today. 2013 Jan 14. pii: S1359-6446(13)00005-6. doi: 10.1016/j.drudis.2013.01.003. [Epub ahead of print]

Should non-inferiority drug trials be banned altogether?

Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ.

Source

Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, David de Wied Building, Universiteitsweg 99, 3584 CG Utrecht, PO Box 80082, Utrecht, The Netherlands. Electronic address: g.wangge@uu.nl.

Abstract

Non-inferiority (NI) trials can be used in a situation when a new drug is expected to have a similar efficacy to its comparator but can offer other advantages over the existing drug, such as a more convenient method of administration or fewer side effects. Here, we discuss the advantages and disadvantages of NI trials from an ethical, methodological and regulatory perspective. We suggest that such trials should be designed to address simultaneously the objective of showing NI with regard to drug efficacy and the objective of establishing superiority of the additional advantages of a drug over its active comparator.